Phase 3 data shows Covaxin 77.8 percent effective against COVID: Lancet
Bharat Biotech has recently announced that the safety and efficacy analysis data from Phase III clinical trials of COVAXIN is peer reviewed and published in The Lancet.
The Lancet peer-review confirms the efficacy analysis which demonstrates COVAXIN to be effective against COVID-19. COVAXIN is the only COVID-19 vaccine to have demonstrated efficacy data from phase III clinical trials against the delta variant at 65.2%.
For more details, check out the full story on the link below:
Phase 3 Data Shows Covaxin 77.8 Percent Effective Against Covid-19, Says Lancet
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd